Attovia Therapeutics, Inc.(ATTO)
$16.64+0.68 (+8.97%)
ATTO
Attovia Therapeutics, Inc. stock forecast
$16.64
At close:+0.68 (+8.97%)
Want to see ATTO full AI Analyst Report?
Attovia Therapeutics, Inc. (ATTO) Stock Forecast & Price Target
13 Followers
ATTO Analyst Ratings
Strong Buy
4Buy0Hold0Sell
Based on 4 analysts giving stock ratings to Attovia Therapeutics, Inc. in the past 3 months
ATTO Stock 12 Month Forecast
Average Price Target
$41.00▲(146.39% Upside)Based on 4 Wall Street analysts offering 12 month price targets for Attovia Therapeutics, Inc. in the last 3 months. The average price target is $41.00 with a high forecast of $45.00 and a low forecast of $34.00. The average price target represents a 146.39% change from the last price of $16.64.
Past 12 Months12 Month ForecastJan2026Oct2026
High$45.00
Average$41.00
Low$34.00
Highest Price TargetHighest$45.00Average Price Target$41.00Lowest Price TargetLowest$34.00
Detailed List of Analyst Forecasts
Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
| Price Target | Article | |||||||
|---|---|---|---|---|---|---|---|---|
| Yigal Nochomovitz | Citi | $30→$34 | buy | 104.33%Upside | Reiterated | 11/10/26 | ||
| Michael Ulz | Morgan Stanley | $39→$40 | buy | 140.38%Upside | Assigned | 11/10/26 | ||
| Brian Abrahams | RBC Capital | $45 | buy | 170.43%Upside | Reiterated | 11/09/26 | ||
| Sam Slutsky | LifeSci Capital | $45 | buy | 170.43%Upside | Reiterated | 09/05/26 |
| Rating | Article | ||||
|---|---|---|---|---|---|
| Yigal NochomovitzCiti | BuyReiterated$30→$34 | 11/10/26 | 104.33%Upside | ||
| Michael UlzMorgan Stanley | BuyAssigned$39→$40 | 11/10/26 | 140.38%Upside | ||
| Brian AbrahamsRBC Capital | BuyReiterated$45 | 11/09/26 | 170.43%Upside | ||
| Sam SlutskyLifeSci Capital | BuyReiterated$45 | 09/05/26 | 170.43%Upside |
Stocks with the Highest Top Analyst Consensus in the General Sector
Best Analysts Covering Attovia Therapeutics, Inc.
3 Months
Success Rate1/3 ratings generated profit
33%
Average Return
-20.60%
Copying Yigal Nochomovitz's trades and holding each position for 3 Months would result in 33.33% of your transactions generating a profit, with an average return of -20.60% per trade.
1 Year
Success Rate1/3 ratings generated profit
33%
Average Return
-20.60%
Copying Yigal Nochomovitz's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of -20.60% per trade.
2 Years
Success Rate1/3 ratings generated profit
33%
Average Return
-20.60%
Copying Yigal Nochomovitz's trades and holding each position for 2 Years would result in 33.33% of your transactions generating a profit, with an average return of -20.60% per trade.
ATTO Analyst Recommendation Trends
| Rating | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|
| Strong Buy | 0 | 3 | 6 | 7 | 7 |
| Buy | 0 | 1 | 2 | 2 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 0 | 4 | 8 | 9 | 8 |
In the current month, ATTO has received 8 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. ATTO average Analyst price target in the past 3 months is 41.00.
ATTO Financial Forecast
ATTO Stock Forecast FAQ
What is ATTO’s average 12-month price target, according to analysts?
Based on analyst ratings, Attovia Therapeutics, Inc.’s 12-month average price target is $41.00.
What is ATTO’s upside potential, based on the analysts’ average price target?
Attovia Therapeutics, Inc. has 146.39% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is ATTO a Buy, Sell or Hold?
Attovia Therapeutics, Inc. has a consensus rating of Strong Buy which is based on 4 buy ratings, 0 hold ratings and 0 sell ratings.
What is Attovia Therapeutics, Inc.’s price target?
The average price target for Attovia Therapeutics, Inc. is $41.00. This is based on 4 12-month price targets, issued in the past 3 months. The highest analyst price target is $45.00, the lowest forecast is $34.00. The average price target represents a 146.39% increase from the current price of $16.64.
What do analysts say about Attovia Therapeutics, Inc.?
Attovia Therapeutics, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 4 Wall Street analysts.
How can I buy shares of ATTO?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
